Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors

[Business Wire] – Bristol-Myers Squibb Company today announced that its Board of Directors has elected Peter J. Arduini to the Board, effective April 1, 2016. Mr. Arduini will serve as a member of the Audit Committee of the Board of Directors, effective May 3, 2016. Read more on this. Bristol-Myers Squibb Company (BMY) , valued at $108.51B, opened at $64.49. Looking at today’s trading action, the company’s one day range from $63.64 to $65.24 with a trailing 52-week range being $51.82 to $70.87. BMY shares are currently priced at 26.02x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -3.21x earnings multiple for the same period. And for dividend hunters, the company pays shareholders $1.52 per share annually in dividends, yielding 2.45%. Consensus earnings for the current quarter by the 17 sell-side analysts covering the stock is an estimate of $0.63 per share, which would be $0.08 worse than the year-ago quarter and a $0.04 sequential increase. Furthermore, our analysis shows the full-year EPS estimate to be $2.38, which would be a $0.37 better when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.19 Billion. If reported, that would be a 3.71% increase over the year-ago quarter. In terms of ratings, Berenberg upgraded BMY from Hold to Buy (Jan 22, 2016). Previously, Piper Jaffray upgraded BMY from Underweight to Neutral. When considering if the stock is under or overvalued, the average price target is $73.70, which is 14.28% above where the stock opened this morning. See more in (NYSE:BMY) Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – SomaLogic Completes Agreement With Bristol-Myers Squibb for Expanded Access to SOMAmer(R) Reagents Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – CORRECTING and REPLACING Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27